TenNor Therapeutics

Based in Suzhou, China, and founded in 2013, TenNor Therapeutics operates as a new antibacterial drug developer, engaged in the treatment of digestive tract infections of new drugs research and development, production and sales. Some enterprises, such as Peking University First Hospital, Beijing Yipukono Technology, and Wuxi New Drug Development, have cooperated with the company. The scientific advisor of the company, Xiaodong Wang, is a director of the Beijing Institute of Life Sciences. In October 2024, TenNor Therapeutics raised over CNY 300 million in series E funding co-led by Zhongshan Venture Capital and AMR Action Fund.

TenNor Therapeutics focuses on bacterial infection and bacterial metabolism-related diseases. The company has a multi-target coupled molecule new drug research and development platform. Its products include TNP-2092IV, TNP-2198, MDR-TB and other series. The products can be used to treat gastrointestinal infections associated with Helicobacter pylori and other pathogenic bacteria, artificial joint infections, bacterial vaginosis, drug-resistant tuberculosis and hospital-acquired gram-negative bacterial infections.

The company generates revenue by developing drugs for the treatment of gastrointestinal infections. The company will use the series E funding to promote the commercialization of TNP-2198, a drug for the treatment of Helicobacter pylori infection, and late-stage clinical trials of TNP-2092, a drug for the treatment of implantable medical device infections.